|
|
|
|
Omeros Licenses PDE7 Compounds for Parkinson's Disease Program
SEATTLE, March 9 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd.for use in its PDE7 program, which is focused on the treatment of movement...
|
|
|
Omeros Licenses PDE7 Compounds for Parkinson's Disease Program
/PRNewswire-FirstCall/ -- Omeros Corporation today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd.for use in its PDE7 program, which is focused on the treatment of movement disorders. Omeros has demonstrated a...
|
|
|
Omeros Corp. (OMER) Obtains Licenses from Asubio Pharma for Compunds to be Used in PDE7 Program
More News related to OMER More News related to Corporate News Omeros Corporation (NASDAQ: OMER) today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd.for use in its PDE7 program, which is focused on the treatment...
|
|
|
Medical News: NxStage Announces New FREEDOM Data Showing The Positive Impact Of Its Daily Home Hemodialysis Therapy On Sleep Quality And Restless Legs Syndrome
Booths # 23-25 at the Annual Dialysis Conference -- NxStage Medical, Inc.Medical News: NxStage Announces New FREEDOM Data Showing The Positive Impact Of Its Daily Home Hemodialysis Therapy On Sleep Quality And Restless Legs Syndrome.
|
|
|
In Obesity, Fat Legs Better than Fat Middles (CME)
Having less abdominal fat but more leg fat may play a role in maintaining metabo In Obesity, Fat Legs Better than Fat Middles (CME).
|
|
|
NxStage Announces New FREEDOM Data Showing the Positive Impact of its Daily Home Hemodialysis Therapy on Sleep Quality and Restless Legs Syndrome
LAWRENCE, Mass.and SEATTLE, March 8 /PRNewswire-FirstCall/ -- Booths # 23-25 at the Annual Dialysis Conference -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the latest interim results from...
|
|
|
NxStage Announces New FREEDOM Data Showing the Positive Impact of its Daily Home Hemodialysis Therapy on Sleep Quality and Restless Legs Syndrome
LAWRENCE, Mass.and SEATTLE, March 8 /PRNewswire-FirstCall/ -- Booths # 23-25 at the Annual Dialysis Conference -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the latest interim results from...
|
|
|
Positive interim results from NxStage Medical's FREEDOM study in RLS
Booths # 23-25 at the Annual Dialysis Conference -- NxStage Medical, Inc.(Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the latest interim results from its ongoing FREEDOM study, which show the significant improvement...
|
|
|
Medical Minute 3-1: Lengthening Legs by 10 Inches
Imagine the doctors saying amputation is your only option.That's the reality for some kids born with leg deformities. But, one doctor is working to give these children more choices. Reporter: Melissa Medalie Email Address: news@wctv.tv Font Size: Kelly...
|
|
|
Obese Kids More Likely to Injure Legs, Ankles, Feet
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Obese Kids More Likely to Injure Legs, Ankles, Feet
Obese kids' injury patterns look different from those of slimmer children, a new Obese Kids More Likely to Injure Legs, Ankles, Feet.
|
|
|
Avoiding Amputation: Lengthening Legs
_ Avoiding Amputation: Lengthening Legs.
|
|
|
Depomed Issues Statement on DM-1796 Pre-NDA Meeting and Horizant Complete Response Letter
Depomed, Inc.announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed further noted it commented on recent public disclosures related to the...
|
|
|
Biopharma Stock Alert for XenoPort Inc. Issued by StockPreacher
DALLAS, Feb.24, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring XenoPort Inc. (Nasdaq:XNPT). The report includes financial, comparative and investment analysis, and industry information you need to know to make an...
|
|
|
Biopharma Stock Alert for XenoPort Inc. Issued by StockPreacher
(GlobeNewswire via COMTEX) ----StockPreacher.com announces an investment report featuring XenoPort Inc.(Nasdaq:XNPT). The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated...
|
|
|
Biopharma Stock Alert for XenoPort Inc. Issued by StockPreacher
(GlobeNewswire via COMTEX) ----StockPreacher.com announces an investment report featuring XenoPort Inc.(Nasdaq:XNPT). The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated...
|
|
|
Biopharma Stock Alert for XenoPort Inc. Issued by StockPreacher
DALLAS, Feb.24, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring XenoPort Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment...
|
|
|
Biopharma Stock Alert for XenoPort Inc. Issued by StockPreacher
DALLAS, Feb.24, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring XenoPort Inc. (Nasdaq: XNPT). The report includes financial, comparative and investment analysis, and industry information you need to know to make an...
|
|
|
Depomed Comments on DM-1796 Pre-NDA Meeting and Horizant Complete Response Letter
- Depomed, Inc.(NASDAQ:DEPO) today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures...
|
|
|
Upgrades & Downgrades: Disney is More Beauty than Beast
Stocks rose for a third straight session as a better than expected Philly Fed Index proved Its Always Sunny in Philadelphia.Were also indeed in The Golden Age for Elizabeths. Elizabeth Arden (RDEN) was upgraded on Wednesday, Liz Claiborne (LIZ) today,...
|
|
|
Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN
Depomed, Inc.(NASDAQ:DEPO) today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related...
|
|
|
GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizant„
GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc.(Nasdaq: XNPT) received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant?(gabapentin enacarbil) Extended-Release Tablets, an...
|
|
|
Depomed Updates On Horizant Complete Response Letter
Depomed has commented on recent public disclosures related to the complete response letter from the FDA regarding the new drug application (NDA) for Horizant (gabapentin enacarbil) extended-release tablets.Horizant is an investigational treatment for...
|
|
|
Depomed Comments on DM-1796 Pre-NDA Meeting and Horizant(R) Compl...
Companies: DepoMed, Inc.(DEPO), GlaxoSmithKline plc (GSK) Depomed, Inc. (NASDAQ:DEPO) today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009.
|
|
|
Depomed Comments on DM-1796 Pre-NDA Meeting and Horizant Complete Response Letter
Companies mentioned in this article: Depomed, Inc.MENLO PARK, Calif. -- (BUSINESS WIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic...
|
